- Home
- MOLN vs ORMP Comparison
MOLN vs ORMP Comparison
Compare MOLN & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | ORMP |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.5M | 170.3M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MOLN | ORMP |
|---|---|---|
| Price | $4.20 | $4.63 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.38 | N/A |
| AVG Volume (30 Days) | 1.4K | ★ 211.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $374.07 | N/A |
| P/E Ratio | ★ N/A | $1.67 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $3.53 | $2.09 |
| 52 Week High | $5.36 | $5.47 |
Technical Indicators
Market Signals| Indicator | MOLN | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 45.69 |
| Support Level | $4.04 | $3.91 |
| Resistance Level | $4.21 | $5.10 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 38.96 | 7.61 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.